

Table S1 CNS efficacy during treatment of ALK inhibitors in ALK rearrangement patients with baseline brain metastasis

Variable	Sequential therapy group	Direct second-generation group
Patients with measurable CNS lesions at baseline		
No. of patients	15	17
Complete response, n (%)	3 (20.0%)	3 (17.6%)
Partial response, n (%)	5 (33.3%)	11 (64.7%)
Stable disease, n (%)	6 (40.0%)	3 (17.6%)
Progressive disease, n (%)	1 (6.7%)	0 (0)
ORR	53.30%	82.40%
DCR	93.30%	100%
Patients with measurable or nonmeasurable CNS lesions at baseline		
No. of patients	28	26
Complete response, n (%)	5 (17.9%)	8 (30.8%)
Progressive disease, n (%)	2 (7.1%)	0 (0)
ORR	35.70%	73.10%
DCR	92.90%	100%
CNS time to progression, months	10.40 (95% CI: 7.42–13.38)	22.40 (95% CI: 18.45–26.35)

ALK, anaplastic lymphoma kinase; CI, confidence interval; CNS, central nervous system; DCR, disease control rate; ORR, objective response rate.